Illness severity and biomarkers in depression: Using a unidimensional rating scale to examine BDNF

Comprehensive Psychiatry

Volumn 75, Issue , 2017, Pages 46-52

  Caldieraro, Marco A ^a,b   Vares, Edgar A ^b   Souza, Lívia H ^b   Spanemberg, Lucas ^b,c   Guerra, Tadeu A ^b   Wollenhaupt Aguiar, Bianca ^b   Ferrari, Pâmela ^b   Nierenberg, Andrew A ^d,e   Fleck, Marcelo P ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; SEROTONIN UPTAKE INHIBITOR; BIOLOGICAL MARKER; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ARTICLE; DEPRESSION; DISEASE SEVERITY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HAMILTON DEPRESSION RATING SCALE D17; HAMILTON DEPRESSION RATING SCALE D2; HAMILTON DEPRESSION RATING SCALE D6; HAMILTON DEPRESSION RATING SCALE D9; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; BIPOLAR DISORDER; BLOOD; EVALUATION STUDY; MAJOR DEPRESSION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; BIOMARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 85015065875     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2017.02.014     Document Type: Article

References (43)

1. [1] Duman, R.S., Heninger, G.R., Nestler, E.J., A molecular and cellular theory of depression. Arch Gen Psychiatry 54 (1997), 597–606.
2. [2] Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., Aubry, J.-M., Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109 (2002), 143–148.
3. [3] Duman, R.S., Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci 16 (2014), 11–27.
4. [4] Miller, B.R., Hen, R., The current state of the neurogenic theory of depression and anxiety. Curr Opin Neurobiol 30 (2015), 51–58, 10.1016/j.conb.2014.08.012.
5. [5] Duman, R.S., Aghajanian, G.K., Synaptic dysfunction in depression: potential therapeutic targets. Science 338 (2012), 68–72, 10.1126/science.1222939.
6. [6] Gass, P., Hellweg, R., Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders?. Int J Neuropsychopharmacol 13 (2010), 1–4, 10.1017/S1461145709991039.
7. [7] Molendijk, M.L., Spinhoven, P., Polak, M., Bus, B.A.A., Penninx, B.W.J.H., Elzinga, B.M., Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 19 (2014), 791–800, 10.1038/mp.2013.105.
8. [8] Jevtović, S., Karlović, D., Mihaljević-Peleš, A., Šerić, V., Vrkić, N., Jakšić, N., Serum brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression. Psychiatr Danub 23 (2011), 363–369.
9. [9] Molendijk, M.L., Bus, B.A.A., Spinhoven, P., Penninx, B.W.J.H., Kenis, G., Prickaerts, J., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16 (2011), 1088–1095, 10.1038/mp.2010.98.
10. [10] Tedlow, J., Fava, M., Uebelacker, L., Nierenberg, A.A., Alpert, J.E., Rosenbaum, J., Outcome definitions and predictors in depression. Psychother Psychosom 67 (1998), 266–270.
11. [11] Østergaard, S.D., Bech, P., Trivedi, M.H., Wisniewski, S.R., Rush, A.J., Fava, M., Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). J Affect Disord 163 (2014), 18–24, 10.1016/j.jad.2014.03.049.
12. [12] Østergaard, S.D., Bech, P., Miskowiak, K.W., Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D6) as outcome measure. J Affect Disord, 2014, 10.1016/j.jad.2014.10.047.
13. [13] Bech, P., Kajdasz, D.K., Porsdal, V., Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 188 (2006), 273–280, 10.1007/s00213-006-0505-1.
14. [14] Fleck, M.P., Poirier-Littre, M.F., Guelfi, J.D., Bourdel, M.C., Loo, H., Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 92 (1995), 168–172.
15. [15] Bech, P., Paykel, E., Sireling, L., Yiend, J., Rating scales in general practice depression: psychometric analyses of the clinical interview for depression and the Hamilton rating scale. J Affect Disord 171 (2015), 68–73, 10.1016/j.jad.2014.09.013.
16. [16] Broen, M.P.G., Moonen, A.J.H., Kuijf, M.L., Dujardin, K., Marsh, L., Richard, I.H., et al. Factor analysis of the Hamilton Depression Rating Scale in Parkinson's disease. Parkinsonism Relat Disord 21 (2015), 142–146, 10.1016/j.parkreldis.2014.11.016.
17. [17] Williams, R.T., Heinemann, A.W., Neumann, H.D., Fann, J.R., Forchheimer, M., Richardson, E.J., et al. Evaluating the psychometric properties and responsiveness to change of 3 depression measures in a sample of persons with traumatic spinal cord injury and major depressive disorder. Arch Phys Med Rehabil 97 (2016), 929–937, 10.1016/j.apmr.2016.01.017.
18. [18] Bagby, R.M., Ryder, A.G., Schuller, D.R., Marshall, M.B., The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. Am J Psychiatry 161 (2004), 2163–2177, 10.1176/appi.ajp.161.12.2163.
19. [19] Isacsson, G., Adler, M., Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr Scand 125 (2012), 453–459, 10.1111/j.1600-0447.2011.01815.x.
20. [20] Licht, R.W., Qvitzau, S., Allerup, P., Bech, P., Validation of the Bech–Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity?. Acta Psychiatr Scand 111 (2005), 144–149, 10.1111/j.1600-0447.2004.00440.x.
21. [21] Shafer, A.B., Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 62 (2006), 123–146, 10.1002/jclp.20213.
22. [22] Prisciandaro, J.J., Tolliver, B.K., An item response theory evaluation of the young mania rating scale and the Montgomery–Asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord 205 (2016), 73–80, 10.1016/j.jad.2016.06.062.
23. [23] Bratås, O., Grønning, K., Forbord, T., Psychometric properties of the Hospital Anxiety and Depression Scale and the General Health Questionnaire-20 in COPD inpatients. Scand J Caring Sci 28 (2014), 413–420, 10.1111/scs.12054.
24. [24] Bech, P., Gram, L.F., Dein, E., Jacobsen, O., Vitger, J., Bolwig, T.G., Quantitative rating of depressive states. Acta Psychiatr Scand 51 (1975), 161–170.
25. [25] Bech, P., Fava, M., Trivedi, M.H., Wisniewski, S.R., Rush, A.J., Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. J Affect Disord 132 (2011), 396–400, 10.1016/j.jad.2011.03.011.
26. [26] Bech, P., The ABC profile of the HAM-D17. Rev Bras Psiquiatr 33 (2011), 109–110.
27. [27] Bech, P., Stage, K.B., Larsen, J.K., Vestergaard, P., Gram, L.F., DUAG, The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine. J Affect Disord 140 (2012), 253–259, 10.1016/j.jad.2012.02.011.
28. [28] Bech, P., Fava, M., Trivedi, M.H., Wisniewski, S.R., Rush, A.J., Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 125 (2012), 342–348, 10.1111/j.1600-0447.2011.01791.x.
29. [29] Kyle, P.R., Lemming, O.M., Timmerby, N., Søndergaard, S., Andreasson, K., Bech, P., The validity of the different versions of the Hamilton Depression Scale in separating remission rates of placebo and antidepressants in clinical trials of major depression. J Clin Psychopharmacol 36 (2016), 453–456, 10.1097/JCP.0000000000000557.
30. [30] Bech, P., The three-fold Hamilton Depression Scale: an editorial comment to Isacsson G, Adler M. Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression (1). Acta Psychiatr Scand 125 (2012), 423–424, 10.1111/j.1600-0447.2011.01817.x.
31. [31] Caldieraro, M.A., Vares, E.A., Spanemberg, L., Radtke Becker, F., Fleck, M.P., Association between core-assigned melancholia and the melancholia subscale of the HAM-D. J Affect Disord 172 (2015), 175–178, 10.1016/j.jad.2014.09.050.
32. [32] Amorim, P., Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr 22 (2000), 106–115, 10.1590/S1516-44462000000300003.
33. [33] Hamilton, M., Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6 (1967), 278–296.
34. [34] Linn, B.S., Linn, M.W., Gurel, L., Cumulative Illness Rating Scale. J Am Geriatr Soc 16 (1968), 622–626.
35. [35] Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41 (1992), 237–248.
36. [36] Steiger, J., Tests for comparing elements of a correlation matrix. Psychol Bull 87 (1980), 245–251, 10.1037/0033-2909.87.2.245.
37. [37] Bus, B.A.A., Molendijk, M.L., Penninx, B.J.W.H., Buitelaar, J.K., Kenis, G., Prickaerts, J., et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 36 (2011), 228–239, 10.1016/j.psyneuen.2010.07.013.
38. [38] Molendijk, M.L., Haffmans, J.P.M., Bus, B.A.A., Spinhoven, P., Penninx, B.W.J.H., Prickaerts, J., et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One, 7, 2012, e48046, 10.1371/journal.pone.0048046.
39. [39] Vinberg, M., Bukh, J.D., Bennike, B., Kessing, L.V., Are variations in whole blood BDNF level associated with the BDNF Val66Met polymorphism in patients with first episode depression?. Psychiatry Res 210 (2013), 102–108, 10.1016/j.psychres.2013.04.023.
40. [40] Bus, B.A.A., Molendijk, M.L., Penninx, B.W.J.H., Buitelaar, J.K., Prickaerts, J., Elzinga, B.M., et al. Low serum BDNF levels in depressed patients cannot be attributed to individual depressive symptoms or symptom cluster. World J Biol Psychiatry 15 (2014), 561–569, 10.3109/15622975.2013.841994.
41. [41] Teche, S.P., Nuernberg, G.L., Sordi, A.O., de Souza, L.H., Remy, L., Ceresér, K.M.M., et al. Measurement methods of BDNF levels in major depression: a qualitative systematic review of clinical trials. Psychiatry Q 84 (2013), 485–497, 10.1007/s11126-013-9261-7.
42. [42] Groves, J.O., Is it time to reassess the BDNF hypothesis of depression?. Mol Psychiatry 12 (2007), 1079–1088, 10.1038/sj.mp.4002075.
43. [43] Rush, A.J., The varied clinical presentations of major depressive disorder. J Clin Psychiatry 68:Suppl. 8 (2007), 4–10.